Ion Beam Applications, SA

Capital/Financing Update • Dec 14, 2012

IBA Announces Fully Approved Financing for Installation of Europe's First Compact Proteus®ONE System

- Full Financing Secured for the Compact Single-Room Proton Therapy System by the Centre Antoine-Lacassagne (CAL) in Nice, France.

Louvain-la-Neuve, Belgium, December 14, 2012 - IBA (Ion Beam Applications S.A.), the global high-tech leader in next generation radiation therapy and diagnostics for the treatment of cancer, is pleased to announce that the Centre Antoine-Lacassagne (CAL), in Nice, France has secured the full project financing for IBA to install its new revolutionary single-room proton therapy system, Proteus®ONE*. When completed, the next generation compact system will be the first of its kind in Europe. It is expected that the project will be completed in 2015.

The project is worth a total of EUR 20 million to IBA. In addition to that, a maintenance and service contract has been signed.

Full details of the project can be found in the June 29, 2012 press release at http://group.ibaworldwide.com/news-and-press

• Ends -

About Proton Therapy

Proton therapy is increasingly considered the most advanced and targeted cancer treatment due to its superior dose distribution and fewer side effects. Protons deposit the majority of their effective energy within a precisely controlled range, directly within the tumor and sparing healthy surrounding tissue.

As access to proton therapy increases in Europe and across the world, IBA continues to demonstrate compassionate innovations with more patient-friendly treatment rooms and more precise therapies. IBA proton therapy systems account for more than half of the world's clinically based proton therapy facilities. To date they include 13 operational proton therapy centers worldwide, and 10 more centers in development.

* Proteus®ONE is the brand name of a new configuration of the Proteus® 235, including some new developments subject to review by Competent Authorities (FDA, European Notified Bodies, et al.) before marketing.

Press release | December 14, 2012 1 | 2

About IBA

IBA (Ion Beam Applications S.A.), is a cancer diagnostics and treatment company and the worldwide technology leader in the field of proton therapy. The Company's expertise lies in the development of next generation proton therapy technologies and radiopharmaceuticals that provide oncology care providers with premium quality services and equipment, including IBA's leading fully integrated IntegraLab® radiopharmacy system, and Dosimetry advanced solutions for Quality Assurance of medical equipment and increased patient safety.

Headquartered in Belgium and employing more than 1,200 people worldwide, IBA currently has installed systems across Europe and the US and is expanding into emerging markets. The Company is focused on building sustainable global growth for investors, providing solutions in the

IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com

Contact

IBA

Jean-Marc Bothy Chief Financial Officer Tel: +32 10 47 58 90

fight against cancer.

Thomas Ralet Vice-President Corporate Communication +32 10 475 890 communication@iba-group.com

For media and investor enquiries:

M:Communications

Mary-Jane Elliott, Amber Bielecka, Claire Dickinson +44 (0) 207 920 2333 IBA@mcomgroup.com

Press release | December 14, 2012 2 | 2

IBA sa. | Chemin du Cyclotron, 3 | 1348 Louvain-la-Neuve | Belgium | Tel.: + 32 10 47 58 11 | Fax: + 32 10 47 58 10 | E-mail: info-worldwide@iba-group.com | www.iba-worldwide.com | RPM Nivelles | VAT: BE 0428.750.985